Official: Merck & Co to acquire Cubist for $8.4 billion

Official: Merck & Co to acquire Cubist for $8.4 billion


Confirming weekend speculation and rumors, US pharma giant Merck & Co this morning said it has entered…

Antibiotics and Infectious diseasesBiotechnologyCubicinCubist PharmaceuticalsMerck & CoMergers & AcquisitionsZerbaxa

Sources say Merck to buy Cubist in $7 billion deal

Sources say Merck to buy Cubist in $7 billion deal


Sources close to the matter say pharma giant Merck & Co has entered negotiations with Cubist Pharmaceuticals…

CubicinCubist PharmaceuticalsMerck & CoMergers & AcquisitionsPharmaceuticalUSA

Cubist Pharmaceuticals voluntarily recalls Cubicin lots in the USA

Cubist Pharmaceuticals voluntarily recalls Cubicin lots in the USA


American biopharmaceutical company Cubist has issued a voluntary recall of certain lots of Cubicin (daptomycin…

Antibiotics and Infectious diseasesBiotechnologyCubicinCubist PharmaceuticalsPhlebitisRegulationThromboembolismUSA

Cubist unveils five-year strategic goals; enters antibiotics collaboration


USA-based Cubist Pharmaceuticals (Nasdaq: CBST) has announced its five-year strategic aspirations - Building…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsEnteregFinancialFundacion MEDINAPharmaceuticalResearch

Hospira challenges Cubist patents on Cubicin


US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) says that it has received a Paragraph IV Notice Letter…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsGenericsHospiraNorth AmericaPatentsPharmaceuticalResearch

Majority of US surveyed MCOs will consider reimbursing novel OPAT agents; report


According to surveyed physicians in the USA, the use of out-patient parenteral antibiotic therapy (OPAT)…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsForest LaboratoriesIvanzMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalTeflaroTheravanceVibativ

Vancomycin continues to dominate MRSA treatment with up to 76% of US specialists using the drug; Study


According to surveyed infectious disease specialists and internists in the USA, as well as hospital patient-level…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsMarkets & MarketingNorth AmericaPfizerPharmaceuticalVancomycinZyvox

Cubist Pharma leaps 14% on settling Cubicin patent litigation with Teva


US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) saw its shares soar 14% to $28.90 in extending trading…

Antibiotics and Infectious diseasesCubicinCubist PharmaceuticalsGenericsNorth AmericaPatentsPharmaceuticalTeva Pharmaceutical Industries



Back to top